文献速递食管与纵隔外科

cT2N0食管癌分期准确性、病理淋巴结受累及总生存的预测因素

Predictors of staging accuracy, pathologic nodal involvement, and overall survival for cT2N0 carcinoma of the esophagus.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-10-19

该多中心回顾性研究纳入26个高容量食管中心的767例cT2N0食管癌患者,比较直接手术、术前化疗和术前放化疗三种策略。结果显示分期准确率仅14%,术前治疗未带来生存优势,肿瘤长度>3.25cm可预测病理淋巴结阳性。

要点

  • cT2N0食管癌分期准确率仅14%,45%病理T分期低于2期,39%病理淋巴结阳性。
  • 直接手术、术前化疗和术前放化疗的中位生存分别为63、70、71个月,无统计学差异(P=.956)。
  • 肿瘤长度>3.25cm可预测病理淋巴结阳性(腺癌OR=2.4,整体OR=2.2)。

核心结论

  • 对于cT2N0M0食管癌,现有治疗选择未显示术前治疗相比直接手术的生存优势。
  • 治疗前肿瘤长度可识别有分期不足(pN+)风险的患者亚组。
  • 分期过度现象提示器官保留方法(内镜下切除)可能在未来适用于适当选择的患者。

研究设计与样本

  • 多中心回顾性协作研究,纳入26个高容量食管中心2002至2012年接受择期切除且分期完整的患者。
  • 共767例患者,其中35%(268例)接受术前治疗(195例术前放化疗,73例术前化疗)。

主要发现

  • 分期准确率为14%(70/499),45%(222例)病理T分期低于2期,39%(195例)病理淋巴结阳性。
  • 术前治疗方式(无、放化疗、化疗)不是结局的预测因素,中位生存分别为63、70、71个月(P=.956)。
  • 肿瘤长度>3.25cm预测直接手术队列的病理淋巴结阳性(OR=2.2,P<.001),腺癌组织学也预测病理淋巴结阳性(OR=2.4,P<.001)。

临床怎么用

  • 对cT2N0食管癌患者,术前治疗未显示生存获益,治疗决策需个体化。
  • 治疗前肿瘤长度>3.25cm提示分期不足风险,可考虑更积极的分期或治疗策略。
  • 分期过度普遍,提示对高度选择的患者可探索内镜下切除等器官保留方法。

局限性

  • 回顾性多中心研究,可能存在选择偏倚和中心间异质性。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Clinical T2N0 esophageal carcinoma is a heterogenous disease frequently complicated by inaccurate staging. Incorrect staging may lead to suboptimal treatment for patients with unidentified local-regionally advanced disease. Therapeutic options for these patients remain controversial. We sought to evaluate the outcomes of patients with cT2N0 who underwent esophagectomy as either primary therapy or after neoadjuvant treatment. METHODS: This was a multi-institutional collaboration of 26 high-volume esophageal centers. Patients with complete staging who underwent elective resection from 2002 to 2012 were included. Three treatment groups were identified; primary esophagectomy, preoperative chemotherapy, and preoperative chemoradiation (CXRT). Pretreatment variables were explored for independent predictors of long-term outcomes. The primary esophagectomy subgroup was evaluated for stage migration. RESULTS: In total, 767 patients were evaluated; 35% (268) had preoperative therapy (195 CXRT, 73 chemotherapy). Staging accuracy was 14% (70/499), with pT < 2 identified in 45% (222) and pN > 0 in 39% (195). Preoperative treatment modality (none, CXRT, chemotherapy) was not identified as a predictor of outcome (median survival 63, 70, 71 months, respectively, P = .956). Longitudinal tumor length >3.25 cm was predictive of pN+ for the primary esophagectomy cohort as well as adenocarcinoma histology only (odds ratio 2.2 and 2.4, respectively, P < .001). CONCLUSIONS: Current treatment options for patients with cT2N0M0 do not reveal a comparative survival advantage to preoperative therapy. Pretreatment tumor length can identify a subgroup of patients at risk for understaging (pN+). The incidence of overstaging suggests that organ-sparing approaches (endoscopic resection) may play a future role in appropriately selected patients.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Predictors of staging accuracy, pathologic nodal involvement, and overall survival for cT2N0 carcinoma of the esophagus. J Thorac Cardiovasc Surg. 2018. PMID: 30558879. doi:10.1016/j.jtcvs.2018.10.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。